Table 2

Prognostic significance of clinical parameters in patients with AE-IIPs determined by logistic regression analysis

Parameter	OR*	95% CI	P value
Univariate
Stable state
Sex, male/female	1.2499	0.2060 to 10.2093	0.8140
Smoking, yes/no	2.2400	0.4135 to 12.3435	0.7376
Diagnosis, IPF/non-IPF	0.6190	0.0765 to 3.5887	0.6037
mMRC, ≤1/≥2	1.1666	0.2251 to 6.9237	0.8560
Stage, I–III/IV	2.7083	0.5354 to 14.8724	0.2275
LTOT before AE, yes/no	2.7083	0.5354 to 14.8724	0.2275
Prednisolone before AE, yes/no	2.2400	0.4135 to 12.3435	0.3431
Antifibrotic drugs before AE, yes/no	14.400	1.6803 to 319.0268	0.0137
At the time of diagnosis of AE
Age, years	0.9929	0.8995 to 1.0986	0.8863
HRCT pattern, diffuse/non-diffuse	9.8000	1.7196 to 83.0325	0.0091
PaO₂/FiO₂ ratio, ≤200/>200	0.7291	0.1425 to 3.8110	0.7014
WCC, /μL	1.0001	0.9999 to 1.0004	0.1607
LDH, U/L	1.0065	1.0007 to 1.0145	0.0244
KL-6, U/mL	1.0009	1.0001 to 1.0020	0.0146
CRP, mg/dL	0.9678	0.8582 to 1.0777	0.6268
FDP, ≥10/<10 mg/L	4.2666	0.7166 to 28.9076	0.1102
Multivariate†
HRCT pattern, diffuse/non-diffuse	13.3634	1.7053 to 285.2057	0.0118
Antifibrotic drugs before AE, yes/no	21.3180	1.6243 to 860.5019	0.0179

*An OR >1 means each categorical parameter or increase in each continuous parameter indicates a high risk of 90-day mortality.
†Multivariate analysis with a stepwise selection procedure was performed to predict 90-day survival using significant parameters with a p value <0.05.
AE, acute exacerbation; CRP, C reactive protein; FDP, fibrin degradation product; FiO₂, fraction of inspired oxygen; HRCT, high-resolution CT; IIPs, idiopathic interstitial pneumonias; IPF, idiopathic pulmonary fibrosis; KL-6, Krebs von den Lungen-6; LDH, lactate dehydrogenase; LTOT, long-term oxygen therapy; mMRC, modified Medical Research Council score; PaO₂, arterial oxygen tension; WCC, white blood cell count.